Literature DB >> 7810534

Arginine vasopressin gene expression in rats with puromycin-induced nephrotic syndrome.

H J Pyo1, S N Summer, M Niederberger, J K Kim, R W Schrier.   

Abstract

Nephrotic syndrome is characterized by water and sodium retention, which leads to edema formation. The nonosmotic stimulation of arginine vasopressin (AVP) release from the pituitary gland has been implicated to be one of the important factors of abnormal water retention in patients with nephrotic syndrome. It is not known, however, whether nephrotic syndrome is associated with stimulation of hypothalamic vasopressin gene expression. Puromycin aminonucleoside is known to cause altered glomerular permeability, which results in experimental nephrotic syndrome in rats. In the present study, therefore, AVP gene expression has been studied in the hypothalamus of rats with puromycin aminonucleoside-induced nephrotic syndrome (PNS). Nephrotic syndrome was induced by a single intravenous injection of puromycin aminonucleoside (50 mg/kg body weight). Nephrotic syndrome was confirmed by urinary protein excretion (control 20.8 +/- 3.5 mg/24 hr v PNS 273.9 +/- 41.4 mg/24 hr; P < 0.0001, n = 6) and serum albumin concentrations (control 4.52 +/- 0.07 g/dL v PNS 2.96 +/- 0.22 g/dL; P < 0.001, n = 6). In PNS rats, plasma AVP was significantly higher than in control rats (control 0.77 +/- 0.10 pg/mL v PNS 2.13 +/- 0.42 pg/mL; P < 0.005, n = 12), even though there were no differences in plasma osmolality (control 292.0 +/- 2.0 mOsm/kg H2O v PNS 290.3 +/- 2.5 mOsm/kg H2O; P = NS, n = 12) or serum sodium concentration (control 142.7 +/- 0.7 v PNS 142.1 +/- 1.1; PNS, n = 12).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7810534     DOI: 10.1016/0272-6386(95)90626-6

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Decreased renal corin expression contributes to sodium retention in proteinuric kidney diseases.

Authors:  Danny Polzin; Henriette J Kaminski; Christian Kastner; Wei Wang; Stephanie Krämer; Stepan Gambaryan; Michael Russwurm; Harm Peters; Qingyu Wu; Alain Vandewalle; Sebastian Bachmann; Franziska Theilig
Journal:  Kidney Int       Date:  2010-07-07       Impact factor: 10.612

2.  Nephrotic syndrome complicated by idiopathic central diabetes insipidus.

Authors:  Takao Konomoto; Etsuko Tanaka; Hideaki Imamura; Mayuko Orita; Hirotake Sawada; Hiroyuki Nunoi
Journal:  Pediatr Nephrol       Date:  2014-01-10       Impact factor: 3.714

3.  Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.

Authors:  Tadashi Okada; Toshifumi Sakaguchi; Ikuji Hatamura; Fumie Saji; Shigeo Negi; Haruhisa Otani; Yasuteru Muragaki; Hiroshi Kawachi; Takashi Shigematsu
Journal:  Clin Exp Nephrol       Date:  2009-05-19       Impact factor: 2.801

4.  Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.

Authors:  Masaki Shimizu; Sayaka Ishikawa; Yusuke Yachi; Masahiro Muraoka; Yuko Tasaki; Hidenori Iwasaki; Mondo Kuroda; Kazuhide Ohta; Akihiro Yachie
Journal:  Pediatr Nephrol       Date:  2013-11-19       Impact factor: 3.714

Review 5.  Dysregulation of ENaC in Animal Models of Nephrotic Syndrome and Liver Cirrhosis.

Authors:  Soo Wan Kim
Journal:  Electrolyte Blood Press       Date:  2006-03

Review 6.  Pathophysiology, Evaluation, and Management of Edema in Childhood Nephrotic Syndrome.

Authors:  Demetrius Ellis
Journal:  Front Pediatr       Date:  2016-01-11       Impact factor: 3.418

Review 7.  The non-immunosuppressive management of childhood nephrotic syndrome.

Authors:  James McCaffrey; Rachel Lennon; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2015-11-10       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.